Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease

28 Sept 2020

Abstract excerpt

Parkinson's disease (PD) affects millions of patients worldwide and is characterized by alpha-synuclein aggregation in dopamine neurons. Molecular tweezers have shown high potential as anti-aggregation agents targeting positively charged residues of proteins undergoing amyloidogenic processes. Here we report that the molecular tweezer CLR01 decreased aggregation and toxicity in induced pluripotent stem...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical Analysis and Sensing Techniques
Share to Neuroinflammation and Neurodegeneration Mechanisms
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32985503
DOI: 10.1038/s41467-020-18689-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s diseasePMID 32985503Read ↗

A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.Semantic proximity Read ↗

A Novel Microfluidic Cell Co-culture Platform for the Study of the Molecular Mechanisms of Parkinson's Disease and Other SynucleinopathiesSemantic proximity Read ↗

A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrilsSemantic proximity Read ↗

An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neuronsSemantic proximity Read ↗

Advanced human iPSC-based preclinical model for Parkinson’s disease with optogenetic alpha-synuclein aggregationSemantic proximity Read ↗

Microphysiological engineering of the capillary interface of substantia nigra dopaminergic neurons to study vascular alterations in Parkinson’s DiseaseSemantic proximity Read ↗

A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's diseaseSemantic proximity Read ↗

Depopulation of α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease modelSemantic proximity Read ↗

Lighting Up Alpha-synuclein Oligomers.Semantic proximity Read ↗

Scalable Human Cellular Models of Parkinson’s Disease Reveal A Druggable Link Between the Angiotensin Receptor 1 and α-Synuclein PathologySemantic proximity Read ↗

WDR44 drives de novo α-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson’s DiseaseSemantic proximity Read ↗

Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.